ON HEART TISSUE REENGINEERING ?
description
Transcript of ON HEART TISSUE REENGINEERING ?
![Page 1: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/1.jpg)
ON HEART TISSUE REENGINEERING ?
JC Chachques, MD PhDGeorges Pompidou European Hospital
Paris, France
Stem cell therapy and CV innovations
What’s new ?
![Page 2: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/2.jpg)
Cardiac Bioassist - Cooperative Work
Teams :
• Olivier Schussler. Ottawa Heart Institut, Canada
• Carlos Semino. MIT + Barcelona Bioengineering Center
• Jorge Genovese. Pittsburgh University, USA
• Jorge Trainini. Avellaneda Hospital, Argentina
![Page 3: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/3.jpg)
HEART FAILURE IN EUROPE
• Heart failure is the single biggest reason for acute hospital admission.
• Around 30 million people in Europe have heart failure and its incidence is increasing.
• More people are living to an old age, and more are surviving a heart attack but with damage to the heart.
![Page 4: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/4.jpg)
PREVALENCE of HEART FAILURE in USA (total population: 305 millions)
![Page 5: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/5.jpg)
Evidence for cardiomyocyte renewal in humans Science 2009; 324: 98-102
Frisen J. et al, Karolinska Institut, Stockholm, Sweden
• Cardiomyocytes are generated also later in life ? • Carbon-14, generated by nuclear bomb tests during the Cold
War, integrated into DNA allows to establish the age of cardiomyocytes in humans
• Results: cardiomyocytes renew, with a gradual decrease from 1% turning over annually at age of 25, to 0.45% at age of 75
• Fewer than 50% of cardiomyocytes are exchanged during a normal life span
• Perspectives: development of therapeutic strategies aimed at stimulating this process in cardiac pathologies
![Page 6: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/6.jpg)
STEM CELL THERAPY and
BIOARTIFICIAL MYOCARDIUM
![Page 7: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/7.jpg)
CARDIAC BIO-ASSIST
![Page 8: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/8.jpg)
CELLS FOR MYOCARDIAL REGENERATION
• Skeletal myoblasts • Bone marrow mononuclear cells • Bone marrow mesenchymal cells• Umbilical cord cells • Adipose tissue stroma cells• Mesothelial cells (from epiploon)• Menstrual blood endometrial cells• Stem cells from the testis• Embryonic cells (pluripotents)
![Page 9: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/9.jpg)
BONE MARROW ASPIRATION
![Page 10: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/10.jpg)
DEVELOPMENT OF
BIO-ARTIFICIAL MYOCARDIUM
![Page 11: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/11.jpg)
BACKGROUNDLimitations of Cellular Cardiomyoplasty
• Cell bio-retention and engraftment within scar tissue is low
• Mortality of implanted cells in ischemic myocardium is high
• In ischemic heart disease the extracellular matrix is pathologically modified
![Page 12: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/12.jpg)
BACKGROUND 2Limitations of Cellular Cardiomyoplasty
• Implanted cells lack both mechanical synchronization and electrical integration, forming « islands of tissue »
Questions and risks:• Excitation-contraction coupling?• Additional excitable cells?• Proarrhythmic?
![Page 13: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/13.jpg)
RATIONALE FOR 3D CARDIAC TISSUE ENGINEERING
• The efficacy and arrhythmia occurrence of stem cell therapy depends on the surviving cell number as well as the delivery route of cells
• A cell-seeded epicardial scaffolds should offert additional niches for cell homing without the risk of a proarrhythmogenic substrate
• Allogeneic cells should be better tolerated in a matrix « niche environment »
![Page 14: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/14.jpg)
Heart extracellular
matrix
Cell niche + cell homing
ml : muscular lacunaecl : capillary lacunae
![Page 15: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/15.jpg)
COMPONENTS OF EXTRACELLULAR MATRIX IN HUMAN HEART
Collagen Type I (80%) : Ventricular chamber geometry, structural support
Collagen Type III (10%): Role in transduction of myocyte shortening during systole
![Page 16: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/16.jpg)
EXTRACELLULAR MATRIX IN ISCHEMIC HEART DISEASE
Collagen Type I : Decreases from 80% to 40%
Collagen Type III : Increases from 10% to 35%
RESULTS : Ventricular dilatation, systolic + diastolic dysfunctions
![Page 17: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/17.jpg)
COLLAGEN TYPE I MATRIX (Pangen 2, France)lyophilised, bovine collagen, 5 x 7 x 0.6 cm
![Page 18: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/18.jpg)
DEVELOPMENT OF ARTIFICIAL MYOCARDIUM
• Collagen matrix (type I)
• 3D and Biodegradable
• Seeded with stem cells
![Page 19: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/19.jpg)
Collagen Matrix without cells seeded with cells
![Page 20: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/20.jpg)
Confocal Microscopy
3D matrix + cells
![Page 21: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/21.jpg)
MATRIX
MATRIX GRAFTED ON EPICARDIUM
![Page 22: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/22.jpg)
PRECLINICAL STUDIESPublished in Tissue Engineering 2007; 13:2681-7
Cell-seeded collagen matrix - 2 Mo Follow-up
![Page 23: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/23.jpg)
BIOARTIFICIAL MYOCARDIUM « MAGNUM » Clinical Trial
M yocardialA ssistance byG rafting aN ew bioartificialU pgradedM yocardium
![Page 24: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/24.jpg)
Rationale
Associate a procedure for myocardial and extracellular matrix regeneration, i.e.
Cellular cardiomyoplasty+
Collagen scaffold grafting
![Page 25: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/25.jpg)
Cellular CMP + Cell Seeded Matrix
![Page 26: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/26.jpg)
Clinical Collagen Matrix Implantation
![Page 27: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/27.jpg)
MAGNUM Clinical Trial
RESULTS
![Page 28: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/28.jpg)
Functional Outcomes: 1 year follow-upFunctional Outcomes: 1 year follow-up
Baseline End FU
p =0.005
NYHA Class
![Page 29: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/29.jpg)
0
5
10
15
20
25
30
35
Baseline End FU
p = 0.04
LV Ejection Fraction (%)
Echocardiographic Study
![Page 30: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/30.jpg)
p = 0.03
100
110
120
130
140
150
Baseline End FU
LV End Diastolic Volume (mL)
Echocardiographic Study
![Page 31: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/31.jpg)
120
130
140
150
160
170
180
190
200
Baseline End FU
LV FILLINGDoppler-derived mitral deceleration time (ms)
p = 0.01
DIASTOLIC FUNCTION
![Page 32: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/32.jpg)
0
2
4
6
8
10
Baseline End FU
Scar Area Thickness (mm)
p = 0.005
Echocardiographic Study
![Page 33: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/33.jpg)
Cellular CMP + MatrixRadioisotopic SPECT sestamibi studies Preop 12 Months
![Page 34: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/34.jpg)
MAGNUM CLINICAL TRIALCONCLUSIONS
• REDUCES THE SIZE AND FIBROSIS OF INFARCT SCARS
• MINIMIZES GLOBAL VENTRICULAR DILATATION
• IMPROVES DIASTOLIC FUNCTION
• INCREASES MYOCARDIAL WALL THICKNESS
• INDUCES MODULATION OF EXTRACELLULAR MATRIX
![Page 35: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/35.jpg)
MAGNUM CLINICAL TRIALCONCLUSIONS
• The implanted matrix contributed to generate the “adequate niche” for native, transplanted and migrating stem cells
![Page 36: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/36.jpg)
![Page 37: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/37.jpg)
FUTURE MATRIX IMPROVEMENTS
• Crosslinking angiogenic growth factors
• Prolong absorption delay by nanotechnologies and additional chemical - physical crosslinking
• Stem cell preconditioning : hypoxic conditions (5%) during culturesin-vitro electrostimulation
![Page 38: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/38.jpg)
Nature Clin Pract Cardiovasc Med 2009; 6: 240-9
Use of arginine-glycine-aspartic (RGD) acid adhesion peptides coupled with a new
collagen scaffold to engineer a myocardium-like tissue graft
Schussler O, Coirault C, Louis-Tisserand M, Chachques JC, Carpentier A, Lecarpentier Y
![Page 39: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/39.jpg)
Frontiers in Bioscience. 2009; 14: 2996-3002
Cardiac pre-differentiation of human mesenchymal stem cells
by electrostimulation
Genovese J, Spadaccio C, Schussler O, Carpentier A, Chachques JC, Patel AN
![Page 40: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/40.jpg)
Biomaterials. 2009; 30: 1156-65
The effect of self-assembling peptide nanofiber scaffolds on
mouse embryonic fibroblast implantation and proliferation
Degano IR, Quintana L, Semino C, et al.
![Page 41: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/41.jpg)
A prototypic synthetic extracellular matrix
•Molecular designed material•Chemically defined•Synthetic process•Highly similarity to natural ECMs
structure: nano-scale fibersself-assembling processbiologically permissive non-competition with natural ECMbiodegradableMechanical properties for soft tissues
•Modification control Building up properties•Transient scaffold•Injecting biological material
![Page 42: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/42.jpg)
A generic peptide scaffold network
Peptide nanofibers = 10-20 nmScaffold pore size = 50-200 nm
![Page 43: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/43.jpg)
RECATABI PROJECT - European Union
![Page 44: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/44.jpg)
RECATABI PROJECT - European Union
![Page 45: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/45.jpg)
![Page 46: ON HEART TISSUE REENGINEERING ?](https://reader035.fdocuments.us/reader035/viewer/2022062305/56814bc8550346895db8a145/html5/thumbnails/46.jpg)
CARMAT ( Carpentier - Matra )Artificial Heart